If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
![]() Headache: The Journal of Head and Face PainVolume 41 Issue 10, Pages 953 - 967 Published Online: 26 Jan 2004 © 2010 American Headache Society Published on behalf of the American Headache Society
Abstract | References | Full Text: HTML, PDF (Size: 86K) | Related Articles | Citation Tracking Butalbital in the Treatment of Headache: History, Pharmacology, and Efficacy Copyright American Headache Society KEYWORDS migraine • acute medication • butalbital • drug overuse • daily headache ABSTRACTAnalgesics containing butalbital compounded with aspirin, acetaminophen, and/or caffeine are widely used for the treatment of migraine and tension-type headache. The butalbital-containing compounds are efficacious in placebo-controlled trials among patients with episodic tension-type headaches. Despite their frequent clinical use for migraine, they have not been studied in placebo-controlled trials among patients with migraine. Barbiturates can produce intoxication, hangover, tolerance, dependence, and toxicity. Butalbital can result in intoxication that is clinically indistinguishable from that produced by alcohol. Butalbital-containing analgesics can produce drug-induced headache in addition to tolerance and dependence. Higher doses can produce withdrawal syndromes after discontinuation. Butalbital-containing analgesics may be effective as backup medications or when other medications are ineffective or cannot be used. Because of concerns about overuse, medication-overuse headache, and withdrawal, their use should be limited and carefully monitored. Accepted for publication July 30, 2001. |
|